Allosteric Regulation of Enzymes
On this page
Direct answer
Phosphofructokinase-1 sits at the gate of glycolysis and answers to many masters: ATP and citrate restrain it, AMP and fructose-2,6-bisphosphate accelerate it, and none of these binds the active site. That is allosteric regulation — effector molecules docking at a regulatory site distant from the catalytic centre, shifting the oligomeric enzyme between a low-activity T (tense) and a high-activity R (relaxed) conformation. Allosteric enzymes display sigmoid rather than hyperbolic substrate saturation, respond steeply to small effector changes, and therefore guard the committed steps of metabolic pathways. K-type modifiers alter the apparent K0.5; V-type modifiers alter Vmax.
What you must remember
- PFK-1 effector map: inhibited by ATP (high-energy charge) and citrate (citrate shuttle signals plentiful precursor); activated by AMP, ADP and — most powerfully — fructose-2,6-bisphosphate.
- Fructose-2,6-bisphosphate: made and broken by the bifunctional PFK-2/FBPase-2; insulin (via dephosphorylation in liver) activates the PFK-2 domain, raising F-2,6-BP and glycolysis; glucagon-cAMP-PKA phosphorylation does the opposite, favouring gluconeogenesis.
- Feedback inhibition: end-product control of committed steps — E. coli aspartate transcarbamoylase (ATCase) is inhibited by CTP and activated by ATP, the textbook bacterial example.
- Sigmoid kinetics: substrate binding is cooperative, so the curve is S-shaped with a K0.5, not a Km; haemoglobin's oxygen dissociation curve is the archetype, shifted by H+, CO2, 2,3-BPG and temperature.
- K-type versus V-type modifiers: K-type shift K0.5 (affinity change — ATP on PFK-1); V-type shift Vmax (catalytic-capacity change). Both are legitimate viva answers when asked "what does an allosteric modifier change?"
- Allosteric versus covalent: allosteric control is instantaneous and reversible; covalent modification (phosphorylation cascades) amplifies signals and lasts longer — glycogen phosphorylase is the standard example.
- Clinical anchor: PFK-1 deficiency is glycogen storage disease VII (Tarui disease) — exercise intolerance, haemolysis with myoglobinuria, no lactic acid rise on exercise.
A hepatocyte after a meal, walked through
Feed the hepatocyte glucose and insulin rises. Insulin signalling dephosphorylates the bifunctional enzyme; with phosphate off, its PFK-2 domain is active and a small amount of fructose-6-phosphate is converted to fructose-2,6-bisphosphate. This tiny amplifier — present at micromolar concentrations — relieves ATP inhibition of PFK-1 and simultaneously inhibits fructose-1,6-bisphosphatase, the gluconeogenic enzyme that would waste carbon going backwards. Glycolysis runs, glucose is trapped, lipogenesis follows. Starve the same cell and glucagon drives cAMP, PKA phosphorylates the bifunctional enzyme, FBPase-2 wins, F-2,6-BP collapses, and the same fructose-6-phosphate now flows toward glucose output. One polypeptide with two opposing activities, one signal metabolite, and the direction of an entire pathway flips — this is the single most examinable allosteric story in biochemistry.
Where students slip
Three slips recur. First, Km is quoted for PFK-1 — allosteric enzymes have K0.5, and using Km marks the answer immediately. Second, students invent a separate "PFK-2 protein": in liver the PFK-2 and FBPase-2 domains sit on one bifunctional polypeptide controlled by a single phosphorylation event, a favourite cross-check question. Third, fructose-1,6-bisphosphate and fructose-2,6-bisphosphate get interchanged under pressure — anchor them as product-versus-signal, one carbon apart in position, worlds apart in function. Examiners also enjoy asking why sigmoid curves exist at all: the answer is sensitivity — a hyperbolic enzyme doubles its rate over a tenfold substrate range, whereas a cooperative enzyme swings from 10 to 90 per cent activity within a threefold range, exactly what a regulatory point needs.
Frequently asked questions
Which is the most potent activator of phosphofructokinase-1?
Fructose-2,6-bisphosphate, present at micromolar concentrations, relieves ATP inhibition and simultaneously inhibits fructose-1,6-bisphosphatase.
Which enzyme synthesises fructose-2,6-bisphosphate?
The PFK-2 domain of the bifunctional PFK-2/FBPase-2 enzyme, activated in liver by insulin-mediated dephosphorylation.
Why do allosteric enzymes show sigmoid kinetics?
Substrate binding is cooperative between subunits, converting T and R states, which makes the rate extremely sensitive to small substrate changes — quantified as K0.5, not Km.
What differentiates K-type from V-type allosteric modifiers?
K-type modifiers change the apparent K0.5 (affinity), while V-type modifiers change Vmax (catalytic capacity) without altering substrate affinity.
Which glycogen storage disease involves PFK-1?
Tarui disease (GSD VII), with exercise intolerance and haemolysis because muscle and erythrocyte glycolysis is blocked at PFK-1.